A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Phase 4 Completed NCT03915964

Summary

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]

From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants) · Days

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
• Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
• CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
• A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
• Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.

All trials